Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19107076 | 0.89 | TSHR (0.36) | TSHRTP53 | |
| SCHEMBL19107071 | 0.89 | TSHR (0.36) | TSHRTP53 | |
| SCHEMBL18895374 | 0.84 | TSHR (0.33) | TSHR | |
| SCHEMBL5482220 | 0.83 | TSHR (0.50) | TSHRTP53CYP2C19NFKB1 | |
| Cadaverine Tartrate SCHEMBL27575429 | 0.83 | TSHR (0.50) | TSHRTP53CYP2C19NFKB1 | |
| SCHEMBL19119831 | 0.81 | TP53 (0.32) | TP53TDP1 | |
| SCHEMBL19119417 | 0.81 | TP53 (0.32) | TP53TDP1 | |
| SCHEMBL23673200 | 0.80 | TP53 (0.50) | TSHRTP53CYP2C19CYP1A2GAA | |
| SCHEMBL44463 | 0.80 | TP53 (0.50) | TSHRTP53CYP2C19CYP1A2GAA | |
| SCHEMBL8557040 | 0.80 | TP53 (0.50) | TSHRTP53CYP2C19CYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052708-A1 | NON-REWETTING O/W (OIL IN WATER) EMULSIFICATION SYSTEM FOR HYDROPHOBIC COMPOUNDS | ORGANOCLICK AB (SE) | 2023-02-16 | — | — | US | claimed |
| WO-2021118451-A1 | NON-REWETTING O/W (OIL IN WATER) EMULSIFICATION SYSTEM FOR HYDROPHOBIC COMPOUNDS | ORGANOCLICK AB (SE) | 2021-06-17 | — | — | WO | claimed |
| CN-104127378-A | mPEG-SC20K-HM-3 polypeptide injection as well as preparation method and application thereof | UNIV CHINA PHARMA | 2014-11-05 | — | — | CN | claimed |
| US-8148402-B2 | Isoindolinone derivatives having inhibitory activity against T-type calcium channel and method for preparation thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-04-03 | — | — | US | claimed |
| US-20230052708-A1 | NON-REWETTING O/W (OIL IN WATER) EMULSIFICATION SYSTEM FOR HYDROPHOBIC COMPOUNDS | ORGANOCLICK AB (SE) | 2023-02-16 | — | — | US | disclosed |
| EP-4028130-A1 | BENZYL AMINE-CONTAINING 5,6-HETEROAROMATIC COMPOUNDS USEFUL AGAINST MYCOBACTERIAL INFECTION | Shionogi & Co., Ltd (JP) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021118451-A1 | NON-REWETTING O/W (OIL IN WATER) EMULSIFICATION SYSTEM FOR HYDROPHOBIC COMPOUNDS | ORGANOCLICK AB (SE) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021050708-A1 | BENZYL AMINE-CONTAINING 5,6-HETEROAROMATIC COMPOUNDS USEFUL AGAINST MYCOBACTERIAL INFECTION | SHIONOGI & CO., LTD. (JP) | 2021-03-18 | — | — | WO | disclosed |
| CN-104127378-A | mPEG-SC20K-HM-3 polypeptide injection as well as preparation method and application thereof | UNIV CHINA PHARMA | 2014-11-05 | — | — | CN | disclosed |
| US-7871445-B2 | Composition for the oxidation dyeing of keratin fibers comprising at least one nonionic derivative of cellulose with at least one hydrophobic substituent, at least one oxidation base of diaminodiazacyclopentene type, and at least one oxidation coupler, an oxidation dyeing process, and kit | L'OREAL S.A. (FR) | 2011-01-18 | — | — | US | disclosed |
| US-20090151090-A1 | COMPOSITION FOR THE OXIDATION DYEING OF KERATIN FIBERS COMPRISING AT LEAST ONE NONIONIC DERIVATIVE OF CELLULOSE WITH AT LEAST ONE HYDROPHOBIC SUBSTITUENT, AT LEAST ONE OXIDATION BASE OF DIAMINODIAZACYCLOPENTENE TYPE, AND AT LEAST ONE OXIDATION COUPLER, AN OXIDATION DYEING PROCESS, AND KIT | L'OREAL S.A. (FR) | 2009-06-18 | — | — | US | disclosed |
| EP-2008658-A1 | Synergistic combination of anthranilamide pyridinureas and benzamide derivatives | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-12-31 | — | — | EP | disclosed |
| US-20070087981-A1 | Water Soluble and Palatable Complexes | LAVIPHARM LABORATORIES, INC. (US) | 2007-04-19 | — | — | US | disclosed |
| EP-1367999-A4 | WATER SOLUBLE AND PALATABLE COMPLEXES | LAVIPHARM LAB INC (US) | 2007-04-18 | — | — | EP | disclosed |
| US-7125564-B2 | Water soluble and palatable complexes | LAVIPHARM LABORATORIES, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1367999-A2 | WATER SOLUBLE AND PALATABLE COMPLEXES | Lavipharm Laboratories, Inc. (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20020147201-A1 | Glycyrrhizin complex | LAVIPHARM LABORATORIES INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002074238-A2 | WATER SOLUBLE AND PALATABLE COMPLEXES | LAVIPHARM LABORATORIES INC. (US) | 2002-09-26 | — | — | WO | disclosed |
| US-6051688-A | AMINO ACID SEQUENCE FOR POLYPEPTIDE OF AT LEAST 6 CONTIGUOUS AMINO ACIDS; FOR DIAGNOSIS AND TREATMENT OF NERVOUS SYSTEM DISORDERS; ANTICONVULSANTS; ANTIISCHEMIC/ANTIHYPOXIC AGENTS; ANTIEPILEPTIC AGENTS; ALZHEIMER'S/PARKINSON'S DISEASES | NPS PHARMACEUTICALS, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-4914125-A | (S)-emopamil for the treatment of migraine | KNOLL AG (DE) | 1990-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147201-A1 | Glycyrrhizin complex | CYP4F12, CYP3A5, CYP4F11 | TSHR 3976/4885TP53 2587/4885CYP2C19 33/4885 |
| US-20070087981-A1 | Water Soluble and Palatable Complexes | SI, GCG, GMPS | TSHR 3873/4885TP53 1122/4885CYP2C19 217/4885 |
| US-20090151090-A1 | COMPOSITION FOR THE OXIDATION DYEING OF KERATIN FIBERS COMPRISING AT LEAST ONE NONIONIC DERIVATIVE OF CELLULOSE WITH AT LEAST ONE HYDROPHOBIC SUBSTITUENT, AT LEAST ONE OXIDATION BASE OF DIAMINODIAZACYCLOPENTENE TYPE, AND AT LEAST ONE OXIDATION COUPLER, AN OXIDATION DYEING PROCESS, AND KIT | KRT18, AOC1, ODC1 | TSHR 4540/4885TP53 2651/4885CYP2C19 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.